No annual revenue total was found in BioStem Technologies, Inc.'s SEC filings.
BioStem Technologies, Inc. (BSEM) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $7.0 million in cash and investments and $223,826 in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$6.74M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BSEM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Pompano Beach, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1658678
- Former names
- BIOSTEM TECHNOLOGIES (until Oct 28, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 7, 2026 | Aug 6, 2026 |
All 75 BioStem Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.